{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:28:17Z","timestamp":1793896097051,"version":"4.8.0"},"reference-count":67,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005046","name":"Natural Science Foundation of Heilongjiang Province, China","doi-asserted-by":"crossref","award":["No.PL2025H 006"],"award-info":[{"award-number":["No.PL2025H 006"]}],"id":[{"id":"10.13039\/501100005046","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cystic fibrosis (CF) is an autosomal recessive disorder caused by pathogenic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and primarily affects the respiratory, digestive, and reproductive systems. Globally, CF is most prevalent among European ancestry, with an incidence rate of approximately 1\/2500 to 1\/3500. In China, the incidence is about 1\/128,000. However, CF is not extremely rare in the Chinese population; rather, its prevalence is significantly underestimated. The CFTR mutation spectrum in China is highly unique, characterized by an extremely low frequency of p.Phe508del. Instead, region-specific mutations such as p.Gly970Asp, p.Ile1023Arg, and p.Arg553Ter predominate, alongside a high proportion of splicing variants and complex rearrangements. A significant proportion of Chinese CF patients primarily present with CF-like phenotypes within the CF-related disease spectrum (such as congenital bilateral absence of the vas deferens and pseudo-Bartter syndrome), exhibiting overlapping features with classic CF but lacking typical respiratory-dominant symptoms. This review examines how these atypical symptoms deviate from the diagnostic pathways established in Western countries. Establishing localised data and functional platforms is a prerequisite for achieving precision medicine. Achieving a transition from symptom-focused care to defect-correcting therapy will require coordinated multicenter collaboration and sustained infrastructure development.<\/jats:p>","DOI":"10.3390\/ijms27062770","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:12:26Z","timestamp":1773853946000},"page":"2770","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Distinct CFTR Mutation Spectrum and Atypical Clinical Presentations in Chinese Patients with Cystic Fibrosis"],"prefix":"10.3390","volume":"27","author":[{"given":"Zixin","family":"Wang","sequence":"first","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guizhi","family":"Zuo","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Shi","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghao","family":"Zhao","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Fan","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Hou","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtian","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Jiamusi University, Jiamusi 154007, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S2213-2600(21)00454-9","article-title":"Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: A 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial","volume":"10","author":"Sutharsan","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jcf.2021.10.011","article-title":"Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment","volume":"21","author":"Raraigh","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/ame2.12180","article-title":"A review of cystic fibrosis: Basic and clinical aspects","volume":"4","author":"Chen","year":"2021","journal-title":"Anim. Models Exp. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jmg-2022-108501","article-title":"Genetic spectrum of Chinese children with cystic fibrosis: Comprehensive data analysis from the main referral centre in China","volume":"60","author":"Shen","year":"2023","journal-title":"J. Med. Genet."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-018-0968-2","article-title":"Clinical and genetic characteristics of cystic fibrosis in CHINESE patients: A systemic review of reported cases","volume":"13","author":"Guo","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13023-022-02279-9","article-title":"Systematic estimation of cystic fibrosis prevalence in Chinese and genetic spectrum comparison to Caucasians","volume":"17","author":"Ni","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/resp.12452","article-title":"Characterization of gene mutations and phenotypes of cystic fibrosis in C hinese patients","volume":"20","author":"Liu","year":"2015","journal-title":"Respirology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jpeds.2015.12.025","article-title":"Clinical phenotypes and genotypic spectrum of cystic fibrosis in Chinese children","volume":"171","author":"Shen","year":"2016","journal-title":"J. Pediatr."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11684-017-0567-y","article-title":"Clinical characterization and diagnosis of cystic fibrosis through exome sequencing in Chinese infants with Bartter-syndrome-like hypokalemia alkalosis","volume":"12","author":"Qiu","year":"2018","journal-title":"Front. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1002\/ppul.26601","article-title":"Clinical and genetic characteristics of children with cystic fibrosis in Henan China: A single-center retrospective analysis","volume":"58","author":"Xu","year":"2023","journal-title":"Pediatr. Pulmonol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"145045","DOI":"10.1016\/j.gene.2020.145045","article-title":"Mutation analysis of the cystic fibrosis transmembrane conductance regulator gene in Chinese congenital absence of vas deferens patients","volume":"765","author":"Luo","year":"2021","journal-title":"Gene"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"148190","DOI":"10.1016\/j.gene.2024.148190","article-title":"Genetic analysis and functional study of novel CFTR variants in Chinese children with cystic fibrosis","volume":"907","author":"Sun","year":"2024","journal-title":"Gene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mgg3.258","article-title":"CFTR founder mutation causes protein trafficking defects in Chinese patients with cystic fibrosis","volume":"5","author":"Leung","year":"2017","journal-title":"Mol. Genet. Genom. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/andr.12592","article-title":"Expanding the phenotypic and genetic spectrum of Chinese patients with congenital absence of vas deferens bearing CFTR and ADGRG 2 alleles","volume":"7","author":"Yuan","year":"2019","journal-title":"Andrology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"15063","DOI":"10.1038\/hgv.2015.63","article-title":"p. G970D is the most frequent CFTR mutation in Chinese patients with cystic fibrosis","volume":"3","author":"Tian","year":"2016","journal-title":"Hum. Genome Var."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s00438-017-1334-0","article-title":"A novel homozygous complex deletion in CFTR caused cystic fibrosis in a Chinese patient","volume":"292","author":"Liu","year":"2017","journal-title":"Mol. Genet. Genom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.4103\/aja2024124","article-title":"Cystic fibrosis-causing variants in Chinese patients with congenital absence of the vas deferens: A cohort and meta-analysis","volume":"27","author":"Lu","year":"2025","journal-title":"Asian J. Androl."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Yang, B., Lei, C., Yang, D., Tan, Z., Guo, T., and Luo, H. (2021). Whole-exome sequencing identified CFTR variants in two consanguineous families in China. Front. Genet., 12.","DOI":"10.3389\/fgene.2021.631221"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Shan, Y., Zhu, Z., Liu, X., Chi, L., Zhang, J., Cheng, L., and Liu, T. (2025). In-depth analysis of cystic fibrosis cases caused by CFTR gene variation and research on the prediction and simulation of the impact on protein function. Front. Pediatr., 13.","DOI":"10.3389\/fped.2025.1574919"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4103\/aja202236","article-title":"Loss-of-function CFTR p. G970D missense mutation might cause congenital bilateral absence of the vas deferens and be associated with impaired spermatogenesis","volume":"25","author":"Hou","year":"2023","journal-title":"Asian J. Androl."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/cdd.2016.118","article-title":"CFTR-\u03b2-catenin interaction regulates mouse embryonic stem cell differentiation and embryonic development","volume":"24","author":"Liu","year":"2017","journal-title":"Cell Death Differ."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41419-018-0311-9","article-title":"CFTR mutation enhances Dishevelled degradation and results in impairment of Wnt-dependent hematopoiesis","volume":"9","author":"Sun","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e13708","DOI":"10.1002\/jcsm.13708","article-title":"Defective Cystic Fibrosis Transmembrane Conductance Regulator Accelerates Skeletal Muscle Aging by Impairing Autophagy\/Myogenesis","volume":"16","author":"Chen","year":"2025","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2018.12.018","article-title":"Defective CFTR promotes intestinal proliferation via inhibition of the hedgehog pathway during cystic fibrosis","volume":"446","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jcf.2020.11.014","article-title":"CFTR plays an important role in the regulation of vascular resistance and high-fructose\/salt-diet induced hypertension in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"64030","DOI":"10.18632\/oncotarget.11747","article-title":"Defective CFTR-\u03b2-catenin interaction promotes NF-\u03baB nuclear translocation and intestinal inflammation in cystic fibrosis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3892\/ijo.2015.2921","article-title":"The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer","volume":"46","author":"Li","year":"2015","journal-title":"Int. J. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"436","DOI":"10.21037\/tcr-21-2296","article-title":"High cystic fibrosis transmembrane conductance regulator expression in childhood B-cell acute lymphoblastic leukemia acts as a potential therapeutic target","volume":"11","author":"Liu","year":"2022","journal-title":"Transl. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-019-1500-x","article-title":"Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis","volume":"10","author":"Villella","year":"2019","journal-title":"Cell Death Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41421-020-00193-7","article-title":"Structural insights into the gating mechanism of human SLC26A9 mediated by its C-terminal sequence","volume":"6","author":"Chi","year":"2020","journal-title":"Cell Discov."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1700162","DOI":"10.1002\/prca.201700162","article-title":"Identification of an Anti-inflammation protein, Annexin A1, in tendon derived stem cells (TDSCs) of cystic fibrosis mice: A comparative proteomic analysis","volume":"12","author":"Liu","year":"2018","journal-title":"Proteom.\u2013Clin. Appl."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1096\/fj.201601181R","article-title":"Cystic fibrosis transmembrane conductance regulator mediates tenogenic differentiation of tendon-derived stem cells and tendon repair: Accelerating tendon injury healing by intervening in its downstream signaling","volume":"31","author":"Liu","year":"2017","journal-title":"FASEB J."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1007\/s00018-018-2755-6","article-title":"Cystic fibrosis transmembrane conductance regulator\u2014Emerging regulator of cancer","volume":"75","author":"Zhang","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","article-title":"From the endoplasmic reticulum to the plasma membrane: Mechanisms of CFTR folding and trafficking","volume":"74","author":"Farinha","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1126\/science.ade2216","article-title":"Molecular structures reveal synergistic rescue of \u0394508 CFTR by Trikafta modulators","volume":"378","author":"Fiedorczuk","year":"2022","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e152186","DOI":"10.1172\/jci.insight.152186","article-title":"CFTR-mediated monocyte\/macrophage dysfunction revealed by cystic fibrosis proband-parent comparisons","volume":"7","author":"Zhang","year":"2022","journal-title":"JCI Insight"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Li, H., Lin, L., Hu, X., Li, C., and Zhang, H. (2019). Liver failure in a Chinese cystic fibrosis child with homozygous R553X mutation. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00036"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11684-021-0846-5","article-title":"Novel mutation c. 1210-3C> G in cis with a poly-T tract of 5T affects CFTR mRNA splicing in a Chinese patient with cystic fibrosis","volume":"16","author":"Zhao","year":"2022","journal-title":"Front. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Donos, M.A., Butnariu, L.I., Anton P\u0103duraru, D.T., Murgu, A.M., Rusu, C., P\u00e2nzaru, M.C., Popescu, R., \u021aarc\u0103, E., Cojocaru, E., and Ghiga, G. (2025). Genetic Heterogeneity Correlated with Phenotypic Variability in 48 Patients with Cystic Fibrosis. J. Clin. Med., 14.","DOI":"10.20944\/preprints202507.0987.v1"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S2213-2600(16)00023-0","article-title":"Progress in therapies for cystic fibrosis","volume":"4","author":"Amaral","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.12998\/wjcc.v7.i15.2110","article-title":"753_754delAG, a novel CFTR mutation found in a Chinese patient with cystic fibrosis: A case report and review of the literature","volume":"7","author":"Wang","year":"2019","journal-title":"World J. Clin. Cases"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Plasschaert, L.W., MacDonald, K.D., and Moffit, J.S. (2024). Current landscape of cystic fibrosis gene therapy. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1476331"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","article-title":"Future therapies for cystic fibrosis","volume":"14","author":"Allen","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"El Makhzen, N., Daimi, H., Bouguenouch, L., and Abriel, H. (2023). The burden of cystic fibrosis in North Africa. Front. Genet., 14.","DOI":"10.3389\/fgene.2023.1295008"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"00856-2020","DOI":"10.1183\/23120541.00856-2020","article-title":"Cystic fibrosis in South Africa: Spectrum of disease and determinants of outcome","volume":"7","author":"Zampoli","year":"2021","journal-title":"ERJ Open Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1513\/AnnalsATS.201606-481FR","article-title":"Cystic Fibrosis in the African Diaspora","volume":"14","author":"Stewart","year":"2017","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_50","first-page":"506","article-title":"Cystic fibrosis primarily presenting with pseudo-Bartter syndrome: A report of three cases and literature review","volume":"26","author":"Zhang","year":"2024","journal-title":"Chin. J. Contemp. Pediatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jcf.2023.12.002","article-title":"Standards for the care of people with cystic fibrosis; establishing and maintaining health","volume":"23","author":"Southern","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","article-title":"Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues","volume":"23","author":"Burgel","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13052-022-01331-5","article-title":"Dornase alfa in cystic fibrosis: Indications, comparative studies and effects on lung clearance index","volume":"48","author":"Terlizzi","year":"2022","journal-title":"Ital. J. Pediatr."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Li, D., and Schneider-Futschik, E.K. (2023). Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis. Antibiotics, 12.","DOI":"10.3390\/antibiotics12030484"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","article-title":"ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis","volume":"43","author":"Wilschanski","year":"2024","journal-title":"Clin. Nutr."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jcf.2024.04.004","article-title":"Update on the diagnosis and management of cystic fibrosis pulmonary exacerbations","volume":"23","author":"Cogen","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcf.2024.08.007","article-title":"Cystic fibrosis foundation position paper: Redefining the CF care model","volume":"23","author":"Goetz","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S2213-2600(22)00434-9","article-title":"Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): Results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials","volume":"11","author":"Ratjen","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcf.2024.02.006","article-title":"In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis","volume":"23","author":"Bihler","year":"2024","journal-title":"J. Cyst. Fibros."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jcf.2025.02.010","article-title":"Strategies used to access CFTR modulators in countries without reimbursement agreements","volume":"24","author":"Guo","year":"2025","journal-title":"J. Cyst. Fibros."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.fitote.2014.11.001","article-title":"Oridonin: A small molecule inhibitor of cystic fibrosis transmembrane conductance regulator (CFTR) isolated from traditional Chinese medicine","volume":"100","author":"Luan","year":"2015","journal-title":"Fitoterapia"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Chen, L., Yu, B., Zhang, Y., Gao, X., Zhu, L., Ma, T., and Yang, H. (2015). Bioactivity-Guided Fractionation of an Antidiarrheal Chinese Herb Rhodiola kirilowii (Regel) Maxim Reveals (-)\u2013Epicatechin-3-Gallate and (-)\u2013Epigallocatechin-3-Gallate as Inhibitors of Cystic Fibrosis Transmembrane Conductance Regulator. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0119122"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1016\/j.cell.2024.04.046","article-title":"Structure-based discovery of CFTR potentiators and inhibitors","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e181836","DOI":"10.1172\/jci.insight.181836","article-title":"Epithelial responses to CFTR modulators are improved by inflammatory cytokines and impaired by antiinflammatory drugs","volume":"9","author":"Rehman","year":"2024","journal-title":"JCI Insight"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"7059","DOI":"10.1038\/s41467-025-62199-7","article-title":"Structure of CFTR bound to (R)-BPO-27 unveils a pore-blockage mechanism","volume":"16","author":"Young","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: Interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41525-022-00299-9","article-title":"Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease","volume":"7","author":"Gong","year":"2022","journal-title":"npj Genom. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2770\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T05:18:37Z","timestamp":1773983917000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/6\/2770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":67,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["ijms27062770"],"URL":"https:\/\/doi.org\/10.3390\/ijms27062770","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]}}}